

## **Onpattro**

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the member identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect<sup>®</sup> 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗖 Same as Ro	equesting Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: 🗆 Same as R Name:	eferring Provider 🗆 Same as Requesting Provider NPI#:
Fax:	Phone:
	to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:	kg
Patient Height:	cm

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. On pattro SGM - 10/2020.

Site	e of Service Questions (SOS):		
	Indicate the site of service requested:  ☐ On Campus Outpatient Hospital ☐ Home infusion, skip to Clinical Questions ☐ Ambulatory surgical, skip to Clinical Questions	☐ Off Campus Outpatient Hospital ☐ Physician office, skip to Clinical Questions ☐ Pharmacy, skip to Clinical Questions ☐ Inpatient hospital, skip to Clinical Questions	
B.	Is the patient less than 21 years old or 65 years of age or older?  ☐ Yes − less than 21 years old, skip to Clinical Criteria Questions ☐ Yes − age 65 years or older, skip to Clinical Criteria Questions ☐ No		
C.	<ul> <li>Is this request to continue previously established treatment with the requested medication?</li> <li>☐ Yes - This is a continuation of an existing treatment.</li> <li>☐ No - This is a new therapy request (patient has not received requested medication in the last 6 months). skip to Clinical Criteria Questions</li> </ul>		
D.	Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids other premedications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, o seizures) during or immediately after an infusion? <i>ACTION REQUIRED: Attach supporting clinical documentation.</i> $\square$ Yes, <i>skip to Clinical Criteria Questions</i> $\square$ No		
E.	Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? <i>ACTION REQUIRED: Attach supporting clinical documentation.</i> $\square$ Yes, <i>skip to Clinical Criteria Questions</i> $\square$ No		
F.	Does the patient have severe venous access is sues that require the use of special interventions only available in the outpatient hospital setting? <i>ACTION REQUIRED: Attach supporting clinical documentation</i> .  □ Yes, skip to Clinical Criteria Questions □ No		
G.	Does the patient have significant behavioral is sues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? <b>ACTION REQUIRED: Attacks upporting clinical documentation.</b> $\square$ Yes $\square$ No		

	Prescriber or Authorized Signature	Date (mm/dd/yy)	
inf X_			
7	I attent that this in forms ation is account a modern a model of J-	aumantation aum outing this	
9.	9. Has the patient demonstrated a beneficial response to Onpattro the neuropathy severity and rate of disease progression as demonstrated Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-polyneuropathy disability (PND) score, FAP disease stage, manu attach medical record documentation confirming improvement	ted by the modified Neuropathy Impairment Diabetic Neuropathy (QoL-DN) total score, al grip strength)? ACTION REQUIRED: If Yes,	
8.	3. Is the request for a continuation of therapy with Onpattro? $\Box$ Ye	is $\square$ No If No, no further questions.	
7.	7. Is the requested medication prescribed by or in consultation with or c) physician specializing in the treatment of amyloidosis?		
6.	6. Will the requested medication be used in combination with either inotersen (Tegsedi) or tafamidis (Vyndaqel, Vyndamax)?    Yes    No		
5.	5. Is the patient a liver transplant recipient? $\square$ Yes $\square$ No		
4.	. Does the patient exhibit clinical manifestations of polyneuropathy of hereditary transthyretin-mediated amyloidos (ATTR-FAP) (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive periphers sensory-motor polyneuropathy)? <i>ACTION REQUIRED: If Yes, attach medical record documentation confirmi clinical manifestations of the condition.</i> $\square$ Yes $\square$ No		
3.	Was the diagnosis confirmed by detection of a mutation in the TTR gene? ACTION REQUIRED: If Yes, attactopy of the TTR gene test result.  \( \subseteq \text{Yes} \) Yes \( \subseteq \text{No} \subseteq \text{Unknown} \)		
2.	2. What is the ICD-10 code?		
1.	<ol> <li>What is the diagnosis?</li> <li>□ Polyneuropathy of hereditary transthyretin-mediated amyloide</li> </ol>	osis 🗆 Other	
	Criteria Questions:		